Google+ Badge

Sunday, February 23, 2014

2/23/14 Health News RESTAURANT CUSTOMERS EXPOSED TO HEPATITIS A - Food Safety Rules Rile Organic Farmers - Liquid Biopsy for Ovarian Cancer

SAN FRANCISCO FOODIES, LET THE PROCESS WORK
Congressmen, and the reporters who cover them, love to be in the know, and when they do not have that insider information they feel a bit weak and vulnerable – I get it.  I also get that the San Francisco foodie community is upset that they are having trouble getting its fix of grass-fed, organic... Continue Reading

HILTON HEAD RESTAURANT CUSTOMERS EXPOSED TO HEPATITIS A
According to the South Carolina Department of Health and Environmental Control (DHEC), customers and staff of Hudson’s Seafood House on the Docks in Hilton Head Island who were present at the restaurant on the evening of February 15, 2014, are encouraged to contact their primary care provider to receive treatment for possible exposure to the... Continue Reading

Planned food safety rules rile organic farmers
Jim Crawford was rushing to load crates of freshly picked organic tomatoes onto trucks heading for an urban farmers market when he noticed the federal agent. A tense conversation followed as the visitor to his farm — an inspector from … Continue reading


Liquid Biopsy Device Monitor Treatment of Ovarian Cancer Patients and Only Costs $1
The ATC Chip identifies ovarian cancer cells floating in ascites( an accumulation of fluid in the stomach).and may be useful for diagnosing other types of malignancies that involve ascites, like pancreatic cancer.
Pathologists will be interested to learn that researchers at Harvard Medical School and Massachusetts General Hospital are developing a “liquid biopsy” technology specifically to enable point-of-care monitoring of the progress of patients undergoing treatment for certain types of cancers. The goal is to develop a method that community hospitals can use to monitor treatment of ovarian cancer patients without the need for expensive medical laboratory equipment. Researchers estimate that their ‘liquid biopsy’ technology could cost as little as $1 per test when eventually cleared for use in clinical settings. The research team created a microchip device—called the ATC chip—that simplifies monitoring of a patient’s response to treatment for ovarian cancer and certain other malignancies. The device captures, isolates, and identifies tumor cells from ascites (ATCs). Continue Reading

No comments:

Post a Comment